Sysmex Inostics

Sysmex Inostics is a molecular diagnostics company that provides testing for physicians, clinical trials, and researchers, offering highly sensitive mutation testing from plasma and serum samples. Our core competency in mutation discovery and detection uses BEAMing Digital PCR and Plasma- SafeSEQ Sequencing (SafeSEQ) technologies. BEAMing and SafeSEQ are the most sensitive techniques available today for blood-based somatic mutation detection from circulating tumor DNA (ctDNA). Our laboratories provide highly customized and sensitive assays to deliver a minimally-invasive, highly sensitive and quantitative, real-time assessment of tumor mutation status to improve the characterization of complex disease and monitor tumor activity. BEAMing and SafeSEQ assays have been used in numerous clinical trials and are the preferred ctDNA assays by oncologists worldwide. We deliver the highest quality ctDNA assays available today in order to assist in guiding therapy and clinical decisions to improve the lives of patients with cancer. Our services include: • Reliable detection below 0.1 % mutant allele frequency • Flexible custom panel development • Efficient clinical intended use-specific panels • Multiple sample types including plasma, blood and bone marrow • CLIA & GCP certified laboratory services • End-to-end clinical development support, from investigational testing to regulatory submission Inostics GmbH was founded in September 2008 in Hamburg, Germany. Effective Oct 1st, 2013 Sysmex Corporation acquired all shares of Inostics GmbH (including its US subsidiary, Inostics Inc.). As a consequence, Inostics has changed its name to Sysmex Inostics GmbH and Sysmex Inostics Inc., and has become a wholly owned subsidiary of Sysmex Corporation.